Report – 2014 Weeks 01-04


One Report – 2014 Weeks 01-04

Abiraterone, Agomelatine, Ambrisentan, Bupivacaine, Dabigatran etexilate, Dorzolamide, Duloxetine, Entecavir, Ezetimibe, Fesoterodine, Imatinib, Indacaterol, Ingenol mebutate, Ivabradine, Lacosamide, Landiolol, Levobupivacaine, Levomilnacipran, Milnacipran, Montelukast, Oxycodone, Oxymorphone, Pregabalin, Rilpivirine, Ropivacaine, Saxagliptin, Solifenacin, Tapentadol, Ticagrelor, Vilazodone

SKU: tcipatent-r-0104-2014 Tag:


There are no reviews yet.

Be the first to review “Report – 2014 Weeks 01-04”

What is a Claimed Intermediate?
A Claimed Intermediate is here defined as a novel pharmaceutical process intermediate which is preferably highly stable, highly isolatable, highly purifiable (optionally with appropriate chirality) and claimed as a compound in a pharmaceutical process patent specification from which it may be subject to a 20 year patent protection term.